GlassScriptPhysician profile
Kelene S Rousey
NPI 1861238198
$2,491.06
in general payments reported to CMS, 2019-2025
34 companies · $1,606 in 2025
The $1,606 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $885 · 2025: $1,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,207 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.11 |
| Education | $283.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $281.13 | 2024-2025 | |
| Janssen Biotech, INC. | $256.84 | 2024-2025 | Tecvayli, Darzalex, Balversa |
| Incyte Corporation | $200.32 | 2024-2025 | Jakafi |
| Genentech USA, INC. | $153.57 | 2024-2025 | Tecentriq, Phesgo, Itovebi |
| Astrazeneca Pharmaceuticals LP | $134.04 | 2024-2025 | Lynparza, Enhertu, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $125.62 | 2025 | Fruzaqla, Ninlaro |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Seagen INC. | $95.00 | 2024 | |
| Merck Sharp & Dohme LLC | $83.63 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Eisai INC. | $82.79 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.66 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $73.64 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $72.16 | 2025 | |
| Jazz Pharmaceuticals INC. | $65.48 | 2024-2025 | |
| Lilly USA, LLC | $61.71 | 2024-2025 | Verzenio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $60.92 | 2025 | Opdualag, Opdivo |
| Tempus Ai, INC | $58.35 | 2025 | Xt Cdx |
| Abbvie INC. | $51.18 | 2024-2025 | |
| Emd Serono, INC. | $50.32 | 2025 | |
| Adaptive Biotechnologies Corporation | $47.95 | 2024-2025 | Clonoseq |
| Aveo Pharmaceuticals, INC. | $37.85 | 2025 | |
| Springworks Therapeutics, INC. | $33.12 | 2025 | Ogsiveo |
| Beone Medicines USA, INC. | $33.06 | 2025 | Tevimbra |
| Blueprint Medicines Corporation | $30.94 | 2025 | Ayvakit |
| Immunocore Limited | $28.97 | 2025 | Kimmtrak |
| Array Biopharma INC | $28.19 | 2025 | Lorbrena |
| Fennec Pharmaceuticals, INC. | $26.62 | 2024 | Pedmark |
| Rigel Pharmaceuticals, INC. | $25.32 | 2025 | Rezlidhia, Gavreto, Tavalisse |
| Genzyme Corporation | $24.37 | 2024 | |
| Sun Pharmaceutical Industries INC. | $22.35 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.90 | 2025 | |
| Alexion Pharmaceuticals, INC. | $18.74 | 2024 | Ultomiris |
| Pharmaand Gmbh | $17.16 | 2025 | Rubraca |
| Tolmar, INC. | $17.16 | 2025 | Eligard, Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelene Rousey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.